AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17638395 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan medoxomil 20 mg once daily (initial treatment)
Number of subjects: 2306
Study 16097995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.d. for 5 days
Number of subjects: 12
Study 16097995 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 12
Study 11871946 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44
Study 11871946 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 44
Study 10464817 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone therapy
Number of subjects: 13
Study 10464817 — intervention group
Group type: COMPARATOR
Intervention: No methylprednisolone therapy (Control)
Number of subjects: 13
Study 8588120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg b.i.d.
Number of subjects: 169
Study 8588120 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 50 mg t.i.d.
Number of subjects: 169
Study 2110077 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of the leading follicle (group A)
Number of subjects: 12
Study 2110077 — intervention group
Group type: COMPARATOR
Intervention: No aspiration of the leading follicle (group B)
Number of subjects: 12
Study 7044013 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (3 x 2 mg/day)
Number of subjects: 5
Study 7044013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31731879 — intervention group
Group type: EXPERIMENTAL
Intervention: SURE test
Number of subjects: 185
Study 31731879 — intervention group
Group type: COMPARATOR
Intervention: Decisional Conflict Scale (DCS)
Number of subjects: 185
Study 29896731 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotype analysis and BACs-on-Beads (BoBs) assay
Number of subjects: 965
Study 29896731 — intervention group
Group type: EXPERIMENTAL
Intervention: BACs-on-Beads (BoBs) assay
Number of subjects: 965
Study 29896731 — intervention group
Group type: COMPARATOR
Intervention: Karyotype analysis
Number of subjects: 965
Study 27074374 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary cognitive-behavioral group sessions (n = 336)
Number of subjects: 686
Study 27074374 — intervention group
Group type: COMPARATOR
Intervention: Written information only (n = 350)
Number of subjects: 686
Study 27074374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cognitive-behavioral sessions and written information)
Number of subjects: 686
Study 24961445 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing information with attributes in a pre‐specified order (Group 1)
Number of subjects: 643
Study 24961445 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing information with attributes in the order of what mattered most last (Group 2)
Number of subjects: 643
Study 24961445 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing information with attributes in the order of what mattered most first (Group 3)
Number of subjects: 643
Study 22342506 — intervention group
Group type: EXPERIMENTAL
Intervention: Long agonist half-dose protocol
Number of subjects: 44
Study 22342506 — intervention group
Group type: COMPARATOR
Intervention: Short agonist protocol without pretreatment
Number of subjects: 44
Study 21140955 — intervention group
Group type: EXPERIMENTAL
Intervention: Full item set of twenty CST items
Number of subjects: 466
Study 21140955 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard short version of fourteen items (CST14)
Number of subjects: 466
Study 21140955 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogeneous, unidimensional set of selected eleven items
Number of subjects: 466
Study 17454966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (stressful intervention)
Number of subjects: 64
Study 17454966 — intervention group
Group type: COMPARATOR
Intervention: Control procedure (non-stressful)
Number of subjects: 64
Study 16490579 — intervention group
Group type: EXPERIMENTAL
Intervention: IDD-P fenofibrate 160-mg tablet plus atorvastatin 10-mg tablet
Number of subjects: 20
Study 16490579 — intervention group
Group type: EXPERIMENTAL
Intervention: IDD-P fenofibrate 160-mg tablet plus simvastatin 10-mg tablet
Number of subjects: 20
Study 16490579 — intervention group
Group type: EXPERIMENTAL
Intervention: IDD-P fenofibrate 160-mg tablet plus ER niacin 500-mg tablet
Number of subjects: 20
Study 16490579 — intervention group
Group type: COMPARATOR
Intervention: IDD-P fenofibrate 160-mg tablet alone
Number of subjects: 20
Study 12582949 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance athletes
Number of subjects: 20
Study 12582949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during hyperaemia
Number of subjects: 20
Study 12582949 — intervention group
Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 20
Study 11391844 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP (250 mg mefloquine, 500 mg sulphadoxine, and 25 mg pyrimethamine per tablet)
Number of subjects: 4019
Study 11391844 — intervention group
Group type: COMPARATOR
Intervention: CQ (150 mg chloroquine base per tablet)
Number of subjects: 4019
Study 11391844 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP
Number of subjects: 4019
Study 11391844 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 4019
Study 8637437 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with focal frontal epilepsy
Number of subjects: 3
Study 8637437 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with primary generalized epilepsy
Number of subjects: 3
Study 8637437 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 3
Study 1379523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazarabine (Ara-AC) at a dose of 2.00 mg m‐2 h‐1
Number of subjects: 0
Study 1379523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazarabine (Ara-AC)
Number of subjects: 0
Study 6507688 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical self-care education (13-session educational intervention)
Number of subjects: 330
Study 6507688 — intervention group
Group type: COMPARATOR
Intervention: Two-hour lecture-demonstration (comparison group)
Number of subjects: 330
Study 31637991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder with co-morbid PTSD (n = 27)
Number of subjects: 82
Study 31637991 — intervention group
Group type: COMPARATOR
Intervention: Bipolar disorder without PTSD
Number of subjects: 82
Study 31637991 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 82
Study 31637991 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflicting appraisals
Number of subjects: 82
Study 29617391 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic Diversion with Duodenal Switch (BPDS)
Number of subjects: 12
Study 29617391 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 12
Study 29617391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 28125733 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (ModEx; 55%VO2max)
Number of subjects: 11
Study 28125733 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (IntEx; 4 min (80%VO2max)/3 min (50% VO2max))
Number of subjects: 11
Study 28125733 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NoEx)
Number of subjects: 11
Study 26094591 — intervention group
Group type: EXPERIMENTAL
Intervention: HPVOPC patients
Number of subjects: 116
Study 26094591 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 116
Study 26094591 — intervention group
Group type: COMPARATOR
Intervention: Partners of HPVOPC patients
Number of subjects: 116
Study 26094591 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 serology
Number of subjects: 116
Study 26094591 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age and higher oral HPV16 copy number
Number of subjects: 116
Study 24274358 — intervention group
Group type: EXPERIMENTAL
Intervention: Instaflex™ Joint Support (3 colored gel capsules per day for 8 weeks)
Number of subjects: 100
Study 24274358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 colored gel capsules per day for 8 weeks)
Number of subjects: 100
Study 21136237 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (GLA)
Number of subjects: 1731
Study 21136237 — intervention group
Group type: COMPARATOR
Intervention: Insulin Detemir (DET)
Number of subjects: 1731
Study 18234045 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg (E40)
Number of subjects: 4312
Study 18234045 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg (E80)
Number of subjects: 4312
Study 18234045 — intervention group
Group type: EXPERIMENTAL
Intervention: sumatriptan 100 mg (S100)
Number of subjects: 4312
Study 18234045 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4312
Study 18234045 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg (E40) and E80
Number of subjects: 4312
Study 15995003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei strain ST11 (10^10 CFU daily for 5 days)
Number of subjects: 230
Study 15995003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 12851564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mime therapy
Number of subjects: 50
Study 10907666 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (daily dose: 18.3 mg)
Number of subjects: 9
Study 10907666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (daily dose: 16 mg)
Number of subjects: 9
Study 10907666 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotic drugs (n=12)
Number of subjects: 9
Study 10907666 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (n=10)
Number of subjects: 9
Study 8888661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5025
Study 8888661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5025
Study 1800390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate (3 x 700 mg/d)
Number of subjects: 48
Study 1800390 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 x 800 mg/d)
Number of subjects: 48
Study 6545038 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information explaining the nature of hypertension and the importance of its treatment; advised to see a physician.
Number of subjects: 147
Study 6545038 — intervention group
Group type: COMPARATOR
Intervention: Control group merely advised by letter to see a physician for raised blood pressure.
Number of subjects: 147
Study 30756280 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based health coaching program (up to 10 calls)
Number of subjects: 923
Study 30756280 — intervention group
Group type: COMPARATOR
Intervention: Information only (one call)
Number of subjects: 923
Study 29247229 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up interviews with structured and extended qualitative questions
Number of subjects: 400
Study 29247229 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Starts with Knowledge‐12 (ASK‐12) questionnaire
Number of subjects: 400
Study 29247229 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD and Asthma Sleep Impact Scale (CASIS) questionnaire
Number of subjects: 400
Study 29247229 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of COPD symptoms
Number of subjects: 400
Study 29247229 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management strategies for exacerbations (antibiotics, resting, corticosteroids)
Number of subjects: 400
Study 25866027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy irradiation with fixation after 24 h (cell recovery)
Number of subjects: 0
Study 25866027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy irradiation with fixation after various time points (double strand break repair kinetics)
Number of subjects: 0
Study 25866027 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded single radiation doses with fixation after 24 h (dose-response)
Number of subjects: 0
Study 24721435 — intervention group
Group type: EXPERIMENTAL
Intervention: High cardiovascular risk management program delivered by village doctors
Number of subjects: 9600
Study 24721435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9600
Study 21700548 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV(HR) auto-test at home
Number of subjects: 9334
Study 21700548 — intervention group
Group type: COMPARATOR
Intervention: Second invitation to Pap test
Number of subjects: 9334
Study 21700548 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV(HR) auto-test
Number of subjects: 9334
Study 21700548 — intervention group
Group type: COMPARATOR
Intervention: Pap test
Number of subjects: 9334
Study 18989693 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine (BA)
Number of subjects: 46
Study 18989693 — intervention group
Group type: EXPERIMENTAL
Intervention: high-intensity interval training (HIIT)
Number of subjects: 46
Study 18989693 — intervention group
Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 46
Study 18989693 — intervention group
Group type: COMPARATOR
Intervention: control (CON)
Number of subjects: 46
Study 18167291 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified autologous pericardial monocuspid valve
Number of subjects: 20
Study 18167291 — intervention group
Group type: COMPARATOR
Intervention: Traditional pericardial monocuspid valve patch
Number of subjects: 20
Study 15451058 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg zinc as gluconate daily for 8 weeks)
Number of subjects: 20
Study 15451058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10770539 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT (randomized controlled trial)
Number of subjects: 160
Study 10770539 — intervention group
Group type: COMPARATOR
Intervention: Observational patients
Number of subjects: 160
Study 9581004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-specific coping skills training (CST)
Number of subjects: 0
Study 9581004 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 0
Study 8180524 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg i.v. injection followed by 20 mg tablet once daily for 6 days)
Number of subjects: 25
Study 8180524 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg i.m. injection followed by 50 mg tablet 4 to 6 hours postoperatively and 50 mg three times daily for 6 days)
Number of subjects: 25
Study 8180524 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (suggested 40 mg dose at induction of anesthesia)
Number of subjects: 25
Study 3540870 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg at dose 1 and 100 mg at doses 2 and 3
Number of subjects: 168
Study 3540870 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg at dose 1 and 50 mg at doses 2 and 3
Number of subjects: 168
Study 3540870 — intervention group
Group type: COMPARATOR
Intervention: Codeine 60 mg at all three doses
Number of subjects: 168
Study 3540870 — intervention group
Group type: COMPARATOR
Intervention: Placebo at all three doses
Number of subjects: 168
Study 31674241 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 460
Study 31674241 — intervention group
Group type: COMPARATOR
Intervention: Standard wound management
Number of subjects: 460
Study 27311454 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based care package involving regular telephone contact and three home visits over two years.
Number of subjects: 30
Study 27311454 — intervention group
Group type: COMPARATOR
Intervention: Usual care consisting of a telephone call and an optional home visit.
Number of subjects: 30
Study 26260733 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Force-sensing catheter
Number of subjects: 300
Study 26260733 — intervention group
Group type: COMPARATOR
Intervention: Control (non-CF catheter)
Number of subjects: 300
Study 26260733 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Force-sensing catheter (optimal CF)
Number of subjects: 300
Study 26260733 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Force-sensing catheter (nonoptimal CF)
Number of subjects: 300
Study 23143561 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon-platinum prostheses
Number of subjects: 30
Study 23143561 — intervention group
Group type: COMPARATOR
Intervention: Nitinol prostheses
Number of subjects: 30
Study 21724341 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly marijuana users
Number of subjects: 236
Study 21724341 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly marijuana smokers
Number of subjects: 236
Study 21724341 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 236
Study 21724341 — intervention group
Group type: COMPARATOR
Intervention: Marijuana users vs non-users
Number of subjects: 236
Study 19739697 — intervention group
Group type: COMPARATOR
Intervention: Memantine monotherapy
Number of subjects: 0
Study 19739697 — intervention group
Group type: COMPARATOR
Intervention: Memantine plus donepezil
Number of subjects: 0
Study 19739697 — intervention group
Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 0
Study 17440998 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated diet (SAT) enriched in saturated fatty acid (SFA) (38% fat, 20% SFA)
Number of subjects: 59
Study 17440998 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (MEDIT) enriched in monounsaturated fatty acid (MUFA) (38% fat, 22% MUFA)
Number of subjects: 59
Study 17440998 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (CHO) (30% fat, 55% CHO)
Number of subjects: 59
Study 17440998 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated diet (SAT)
Number of subjects: 59
Study 15450839 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity 2-octylcyanoacrylate
Number of subjects: 209
Study 15450839 — intervention group
Group type: COMPARATOR
Intervention: Commercially available devices
Number of subjects: 209
Study 15450839 — intervention group
Group type: EXPERIMENTAL
Intervention: New 2-octylcyanoacrylate formulation
Number of subjects: 209
Study 15450839 — intervention group
Group type: COMPARATOR
Intervention: Old 2-octylcyanoacrylate formulation
Number of subjects: 209
Study 11170948 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily)
Number of subjects: 203
Study 11170948 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g intravenously twice daily)
Number of subjects: 203
Study 11170948 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid and Vancomycin
Number of subjects: 203
Study 9924006 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Cu/l (Control)
Number of subjects: 60
Study 9924006 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg Cu/l
Number of subjects: 60
Study 9924006 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg Cu/l
Number of subjects: 60
Study 9924006 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Cu/l
Number of subjects: 60
Study 7584882 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchidectomy
Number of subjects: 27
Study 7584882 — intervention group
Group type: COMPARATOR
Intervention: Combined oral and intramuscular estrogens
Number of subjects: 27
Study 2318372 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment consisting of monthly check-ups, home blood pressure measurements, and lifestyle advice (salt restriction, weight reduction, physical activity, reduction of alcohol and tobacco)
Number of subjects: 400
Study 2318372 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment
Number of subjects: 400
Study 6965324 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (10-minute treatment)
Number of subjects: 21
Study 31397587 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterstereotypic condition (uncontrollable explanation of obesity)
Number of subjects: 350
Study 31397587 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotypic condition (emphasized lifestyle choices)
Number of subjects: 350
Study 31397587 — intervention group
Group type: COMPARATOR
Intervention: Control condition (weight not addressed)
Number of subjects: 350
Study 30640655 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.375% ropivacaine (Group A)
Number of subjects: 80
Study 30640655 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.375% ropivacaine (Group B)
Number of subjects: 80
Study 28494915 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW group (36 patients)
Number of subjects: 77
Study 28494915 — intervention group
Group type: COMPARATOR
Intervention: FAST group (41 patients)
Number of subjects: 77
Study 28494915 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW group
Number of subjects: 77
Study 28494915 — intervention group
Group type: COMPARATOR
Intervention: FAST group
Number of subjects: 77
Study 26529533 — intervention group
Group type: EXPERIMENTAL
Intervention: Coflex‐F rigid interspinous spacer
Number of subjects: 90
Study 26529533 — intervention group
Group type: COMPARATOR
Intervention: 4‐point transpedicular rod fixation
Number of subjects: 90
Study 26529533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (interbody fusion with Pezo‐T PEEK cage)
Number of subjects: 90
Study 22727783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment craving measured using the Obsessive subscale of the Obsessive Compulsive Drinking Scale
Number of subjects: 260
Study 22727783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment depressive mood
Number of subjects: 260
Study 20932667 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) - three cycles of cisplatin-based chemotherapy followed by CHART
Number of subjects: 46
Study 20932667 — intervention group
Group type: COMPARATOR
Intervention: CHART alone
Number of subjects: 46
Study 20932667 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 46
Study 20932667 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT)
Number of subjects: 46
Study 19167144 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-group support intervention combined with monthly somatic healthcare (n=159)
Number of subjects: 326
Study 19167144 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=167)
Number of subjects: 326